石药集团(01093)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01093 石药集团

未开盘 04-16 16:08:30

5.430

-0.170

-3.04%

最高5.600	最低5.350	成交量1.10亿
今开5.600	昨收5.600	日振幅4.46%
总市值626.84亿	流通市值626.84亿	总股本115.44亿
成交额5.97亿	换手率0.95%	流通股本115.44亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01093","market":"HK","secType":"STK","nameCN":"石药集团","latestPrice":5.43,"timestamp":1744790910028,"preClose":5.6,"halted":0,"volume":109623380,"delay":0,"floatShares":11544000000,"shares":11544000000,"eps":0.39180329142803927,"marketStatus":"未开盘","change":-0.17,"latestTime":"04-16 16:08:30","open":5.6,"high":5.6,"low":5.35,"amount":596800086,"amplitude":0.044643,"askPrice":5.44,"askSize":1112000,"bidPrice":5.43,"bidSize":688000,"shortable":3,"etf":0,"ttmEps":0.39178310184538495,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1744853400000},"marketStatusCode":0,"adr":0,"listingDate":772128000000,"exchange":"SEHK","adjPreClose":5.6,"dividendRate":0.047624,"openAndCloseTimeList":[[1744767000000,1744776000000],[1744779600000,1744790400000]],"volumeRatio":0.607823,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"CSP.HK","impliedVol":0.5559,"impliedVolPercentile":0.9028},"requestUrl":"/m/hq/s/01093/wiki","defaultTab":"wiki","newsList":[{"id":"2527260717","title":"石药集团04月16日主力净流出1963万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2527260717","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2527260717?lang=zh_cn&edition=full","pubTime":"2025-04-16 16:17","pubTimestamp":1744791433,"startTime":"0","endTime":"0","summary":"04月16日, 石药集团股价跌3.04%，报收5.43元，成交金额5.97亿元，换手率0.95%，振幅4.46%，量比0.61。石药集团今日主力资金净流出1963万元，上一交易日主力净流入4109万元。该股近5个交易日上涨9.84%，主力资金累计净流入1.73亿元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入2.70亿元，其中净流入天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416174250a45aeccc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416174250a45aeccc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1226288170.HKD","LU1152091168.USD","SG9999004220.SGD","LU0067412154.USD","IE00B031HY20.USD","LU1993786604.SGD","LU1226287529.USD","IE00B5MMRT66.SGD","IE00BZ08YS42.EUR","BK1515","IE0008369823.USD","LU1951186391.HKD","LU1226287792.SGD","BK1521","LU0140636845.USD","LU1226287875.USD","LU1960683339.HKD","BK1191","IE00B543WZ88.USD","LU0072913022.USD","LU1152091754.HKD","LU0880133367.SGD","IE00BZ08YR35.GBP","LU0501845795.SGD","LU1807302812.USD","IE0008368742.USD","IE00BZ08YT58.USD","LU1226288253.USD","01093","LU1008478684.HKD","LU0326950275.SGD"],"gpt_icon":0},{"id":"2527236982","title":"石药集团下跌3.93%，报5.38元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2527236982","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2527236982?lang=zh_cn&edition=full","pubTime":"2025-04-16 13:12","pubTimestamp":1744780340,"startTime":"0","endTime":"0","summary":"4月16日，石药集团(01093)盘中下跌3.93%，截至13:00，报5.38元/股，成交3.02亿元。石药集团有限公司是香港的一家医药上市企业，主要业务为成药和原料药生产，并以创新药为核心发展战略，在神经系统疾病、抗肿瘤、抗感染及心血管疾病等治疗领域具有强大的产品组合。同时该公司拥有一支国际化的研发团队，专注于小分子靶向药物、纳米药物、单抗药物、双抗药物、抗体偶联药物以及免疫领域生物药物的发现、研究及开发。截至2024年年报，石药集团营业总收入290.09亿元、净利润43.28亿元。4月15日，第一上海证券维持买入评级,目标价7.14港元。本文源自：金融界作者：行情君","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416131534a45aa1e4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416131534a45aa1e4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1993786604.SGD","LU1226288170.HKD","IE00BZ08YR35.GBP","LU0072913022.USD","IE00BZ08YT58.USD","LU1807302812.USD","SG9999004220.SGD","LU0326950275.SGD","LU0067412154.USD","IE0008369823.USD","LU1226287875.USD","IE00B031HY20.USD","LU1152091168.USD","LU1951186391.HKD","BK1515","BK1521","BK1191","IE0008368742.USD","LU0880133367.SGD","LU0501845795.SGD","LU1226287529.USD","LU1226288253.USD","IE00B543WZ88.USD","LU1008478684.HKD","LU1226287792.SGD","LU1152091754.HKD","IE00B5MMRT66.SGD","01093","LU0140636845.USD","IE00BZ08YS42.EUR","LU1960683339.HKD"],"gpt_icon":0},{"id":"2527238501","title":"【券商聚焦】第一上海维持石药集团(01093)买入评级 指公司新产品放量引领重回增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2527238501","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2527238501?lang=zh_cn&edition=full","pubTime":"2025-04-16 12:26","pubTimestamp":1744777605,"startTime":"0","endTime":"0","summary":"金吾财讯 | 第一上海发研报指，石药集团 2024年实现收入290.1亿元，其中成药收入237.4亿元，原料药及功能食品52.7亿元。该行表示，公司集采影响持续消化，新产品放量引领重回增长：分版块看，公司神经系统板块收入96.5亿元。明复乐脑卒中适应症2025年起纳入医保目录，将进一步加速放量，助力其成为10亿大单品。而创新产品陆续获批上市并持续放量，预计全年将提供超15亿元的增量。2025年公司成药板块有望实现正增长。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1957309","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00227","01093"],"gpt_icon":0},{"id":"2527472260","title":"智通港股早知道 | 敦煌网爆火冲击美区App Store免费iPhone应用程序总榜榜首 欧盟与美谈判进展甚微","url":"https://stock-news.laohu8.com/highlight/detail?id=2527472260","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2527472260?lang=zh_cn&edition=full","pubTime":"2025-04-16 07:33","pubTimestamp":1744759982,"startTime":"0","endTime":"0","summary":"4月15日，美区App Store显示，在购物类软件中，DHgate、淘宝和SHEIN成为排名前3的免费iPhone应用程序。截至发稿，在美区App Store免费iPhone应用程序总榜中，敦煌网目前排名第2，仅次于ChatGPT，淘宝则排名第8。据Appfigures统计，敦煌网在美区App store的免费iPhone应用软件排行榜上长期处于300名左右。Appfigures数据显示，除了美国，敦煌网在加拿大、澳大利亚等国家呈现出相似的趋势，目前为加区App store的免费iPhone应用软件排行榜第2，澳区榜单第4。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1279254.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4581","MACW.SI","LU0053666078.USD","LU0348723411.USD","HSTECH","LU0353189763.USD","LU1066053197.SGD","SG9999018865.SGD","LU0077335932.USD","YANG","LU0957791311.USD","LU2361045086.USD","01093","LU0683600562.USD","SG9999014542.SGD","LU1316542783.SGD","IE0034235303.USD","BK4507","LU1960683339.HKD","LU2065171311.SGD","LU0154236417.USD","LU2023250330.USD","LU0661504455.SGD","LU2168564065.EUR","LU1251922891.USD","LU1720051017.SGD","LU2054465674.USD","LU1066051225.USD","IE00B3SWFQ91.USD","LU2168564149.EUR","LU1868836757.USD","LU0256863902.USD","LU1066051498.USD","LU2236285917.USD","LU2360032135.SGD","IE00BKDWB100.SGD","LU2097828805.USD","81024","IE00BZ08YT58.USD","LU2461242641.AUD","LU2543165471.USD","LU0823434740.USD","LU1226287875.USD","LU1852331112.SGD","LU0203202063.USD","SG9999014914.USD"],"gpt_icon":1},{"id":"2527941355","title":"石药集团：磷酸奥司他韦干混悬剂获药品注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2527941355","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2527941355?lang=zh_cn&edition=full","pubTime":"2025-04-15 20:16","pubTimestamp":1744719379,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1515","LU1226287875.USD","LU1008478684.HKD","LU1960683339.HKD","LU1226288170.HKD","IE00BZ08YR35.GBP","LU1152091754.HKD","IE00B543WZ88.USD","01093","IE00BZ08YS42.EUR","LU1226288253.USD","LU0140636845.USD","LU1993786604.SGD","LU1152091168.USD","IE0008368742.USD","IE00B031HY20.USD","LU0501845795.SGD","IE00BZ08YT58.USD","SG9999004220.SGD","IE0008369823.USD","LU0326950275.SGD","LU0072913022.USD","IE00B5MMRT66.SGD","LU1226287529.USD","LU1951186391.HKD","LU1226287792.SGD","LU0880133367.SGD","BK1521","BK1191","LU0067412154.USD","LU1807302812.USD"],"gpt_icon":0},{"id":"2527935034","title":"石药集团(01093)：磷酸奥司他韦干混悬剂获药品注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2527935034","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2527935034?lang=zh_cn&edition=full","pubTime":"2025-04-15 18:23","pubTimestamp":1744712602,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团(01093)发布公告，集团开发的磷酸奥司他韦干混悬剂(0.36g)(该产品)已获得中华人民共和国国家药品监督管理局颁发的药品注册批件，并视同通过仿制药质量和疗效一致性评价。磷酸奥司他韦是一种选择性的流感病毒神经氨酸酶抑制剂，能够通过抑制甲型和乙型流感病毒的神经氨酸酶活性来抑制病毒从被感染的细胞中释放，从而减少甲型或乙型流感病毒的播散。该产品适用于成人和2周龄及以上儿童的甲型和乙型流感治疗，以及适用于1岁及1岁以上人群的甲型和乙型流感的预防。该产品的获批将进一步丰富集团在抗感染治疗领域的产品线。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1278960.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B5MMRT66.SGD","LU1960683339.HKD","LU1807302812.USD","LU0140636845.USD","IE00B543WZ88.USD","LU0067412154.USD","IE0008369823.USD","LU1993786604.SGD","LU0072913022.USD","LU1152091168.USD","LU1008478684.HKD","BK1191","LU1152091754.HKD","IE00BZ08YT58.USD","LU1226287529.USD","LU0326950275.SGD","LU0880133367.SGD","BK1521","BK1515","IE00BZ08YS42.EUR","LU0501845795.SGD","IE00B031HY20.USD","LU1951186391.HKD","LU1226288170.HKD","IE0008368742.USD","SG9999004220.SGD","IE00BZ08YR35.GBP","01093","LU1226287875.USD","LU1226287792.SGD","LU1226288253.USD"],"gpt_icon":0},{"id":"2527451573","title":"中证海外内地股医药卫生指数报1356.23点，前十大权重包含石药集团等","url":"https://stock-news.laohu8.com/highlight/detail?id=2527451573","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2527451573?lang=zh_cn&edition=full","pubTime":"2025-04-15 15:37","pubTimestamp":1744702642,"startTime":"0","endTime":"0","summary":"金融界4月15日消息，A股三大指数收盘涨跌不一，中证海外内地股医药卫生指数 报1356.23点。数据统计显示，中证海外内地股医药卫生指数近一个月下跌4.91%，近三个月上涨23.87%，年至今上涨26.98%。从中证海外内地股医药卫生指数持仓的市场板块来看，香港证券交易所占比49.57%、纳斯达克全球精选市场证券交易所占比44.12%、纳斯达克股票市场证券交易所占比6.31%。从中证海外内地股医药卫生指数持仓样本的行业来看，医药卫生占比100.00%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041515451197384ee6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041515451197384ee6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE0008368742.USD","IE00BZ08YT58.USD","LU1152091168.USD","LU1226287792.SGD","01093","LU0140636845.USD","LU1951186391.HKD","LU1807302812.USD","IE00B5MMRT66.SGD","LU1226287529.USD","BK1515","SG9999004220.SGD","LU1226288170.HKD","LU1993786604.SGD","IE00BZ08YS42.EUR","LU0072913022.USD","LU1960683339.HKD","LU0880133367.SGD","LU1008478684.HKD","IE00BZ08YR35.GBP","LU1152091754.HKD","BK1191","BK1521","LU1226287875.USD","IE00B543WZ88.USD","LU1226288253.USD","LU0326950275.SGD","IE00B031HY20.USD","IE0008369823.USD","LU0067412154.USD","LU0501845795.SGD"],"gpt_icon":0},{"id":"2527171806","title":"金十数据整理：每日港股市场要闻速递（4月15日 周二）","url":"https://stock-news.laohu8.com/highlight/detail?id=2527171806","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2527171806?lang=zh_cn&edition=full","pubTime":"2025-04-15 08:55","pubTimestamp":1744678551,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["01458","IE0008368742.USD","603259","SGXZ49509284.SGD","02359","BK1191","LU0072913022.USD","09930","BK1237","LU2495084118.USD","LU0345780281.USD","BK0070","06049","BK1604","LU2125910500.SGD","BK1589","BK1521","LU0326950275.SGD","LU1720050803.USD","LU0463099449.HKD","YANG","01668","SG9999004220.SGD","BK1583","LU1226287792.SGD","LU0327786744.USD","01093","01088","BK1515","BK1127","LU1794554557.SGD","HK0000320264.USD","161032","LU1960683339.HKD","LU1008478684.HKD","07226","LU0821914370.USD","LU1807302812.USD","HSTECH","01787","06060","600547","IND.AU","HSCEI","601088","02899","BK1538","BK0196","601899"],"gpt_icon":0},{"id":"2527122202","title":"智通港股早知道 | 陈茂波已指示香港证监会及港交所 为中概股回流香港上市做准备","url":"https://stock-news.laohu8.com/highlight/detail?id=2527122202","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2527122202?lang=zh_cn&edition=full","pubTime":"2025-04-15 07:25","pubTimestamp":1744673143,"startTime":"0","endTime":"0","summary":"陈茂波：已指示证监会及港交所，为中概股回流香港上市做准备香港财政司长陈茂波于 4 月 13 日在司长随笔上表示，针对全球最新变化，他已指示证监会和港交所做好准备，若于海外上市的中概股希望回流，必须让香港成为它们首选的上市地。相关中概股在香港双重主要或第二上市，有助公司获得重新估值机会。香港金管局表示，港元市场交易平稳有序，港元近期走势仍与联系汇率制度的运作一致。该计划尚需中国证监会核准及联交所批准。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1278586.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02899","HK0000320264.USD","HSTECH","HK0000306701.USD","LU0572944931.SGD","01093","LU0821914370.USD","LU1226288253.USD","TTTN","03931","BK1592","LU0880133367.SGD","BK1594","LU1008478684.HKD","LU0181495838.USD","LU1251922891.USD","LU0345780281.USD","LU2039709279.SGD","LU0828237940.HKD","LU0327786744.USD","LU0244354667.USD","LU2097828631.EUR","SG9999004220.SGD","IE00B543WZ88.USD","LU1719994722.HKD","YANG","LU1226287529.USD","BK1198","LU1720050803.USD","IE00BZ08YT58.USD","LU1960683339.HKD","LU1993786604.SGD","LU1226287875.USD","LU1831875114.USD","01787","HK0000306685.HKD","IE00B031HY20.USD","LU0501845795.SGD","LU2097828474.EUR","LU2097828714.EUR","LU1226287792.SGD","BK1521","LU1226288170.HKD","LU0140636845.USD","IE0008369823.USD","LU1152091168.USD","LU1303224171.USD","IE00BZ08YS42.EUR"],"gpt_icon":1},{"id":"2527138162","title":"石药集团(01093)：SYS 6041(抗体偶联药物)获美国临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2527138162","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2527138162?lang=zh_cn&edition=full","pubTime":"2025-04-14 17:50","pubTimestamp":1744624248,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团(01093)发布公告，集团开发的SYS 6041( 抗体偶联药物 )的试验性新药(IND)申请已获得美国食品药品监督管理局(FDA)批准，可以在美国开展临床研究。该产品已于2025年1月获得中华人民共和国国家药品监督管理局批准在中国开展临床试验。该产品为一款单克隆抗体偶联药物，与肿瘤表面的特异性受体结合，通过内吞作用进入细胞并释放毒素，达到杀伤肿瘤细胞的作用。本次获批的适应症为晚期实体瘤。临床前研究显示，该产品对多种癌症均有较好的抗肿瘤作用，具有较高的临床开发价值。该产品已在国内外提交多件专利申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1278203.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","IE00BZ08YR35.GBP","LU1226287875.USD","LU1951186391.HKD","BK1191","LU0326950275.SGD","IE00BZ08YS42.EUR","LU1008478684.HKD","LU1152091168.USD","LU1226288253.USD","LU1807302812.USD","LU1226287792.SGD","IE00BZ08YT58.USD","LU1226288170.HKD","LU1226287529.USD","IE00B031HY20.USD","LU0067412154.USD","BK1515","03347","LU1152091754.HKD","BK1521","LU0140636845.USD","01093","BK1583","LU1993786604.SGD","LU0072913022.USD","LU0880133367.SGD","IE00B5MMRT66.SGD","LU0501845795.SGD","IE00B543WZ88.USD","LU1960683339.HKD","IE0008369823.USD","IE0008368742.USD","SG9999004220.SGD","BK1576"],"gpt_icon":0},{"id":"2527710279","title":"石药集团(01093)上涨10.25%，报5.81元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2527710279","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2527710279?lang=zh_cn&edition=full","pubTime":"2025-04-14 14:15","pubTimestamp":1744611357,"startTime":"0","endTime":"0","summary":"4月14日，石药集团(01093)盘中上涨10.25%，截至14:15，报5.81元/股，成交9.3亿元。石药集团有限公司是香港的一家医药上市企业，主要业务为成药和原料药生产，并以创新药为核心发展战略，在神经系统疾病、抗肿瘤、抗感染及心血管疾病等治疗领域具有强大的产品组合。同时该公司拥有一支国际化的研发团队，专注于小分子靶向药物、纳米药物、单抗药物、双抗药物、抗体偶联药物以及免疫领域生物药物的发现、研究及开发。截至2024年年报，石药集团营业总收入290.09亿元、净利润43.28亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/14141549516395.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["IE00B031HY20.USD","LU0140636845.USD","IE00BZ08YT58.USD","SG9999004220.SGD","LU1993786604.SGD","01093","IE0008369823.USD","LU1152091754.HKD","LU1807302812.USD","LU1226287529.USD","LU0326950275.SGD","BK1521","LU1960683339.HKD","LU1226287875.USD","LU0501845795.SGD","LU0880133367.SGD","LU1152091168.USD","LU0072913022.USD","IE00BZ08YS42.EUR","LU1226287792.SGD","LU1951186391.HKD","IE0008368742.USD","IE00BZ08YR35.GBP","LU1226288170.HKD","LU0067412154.USD","BK1515","IE00B543WZ88.USD","LU1226288253.USD","BK1191","LU1008478684.HKD","IE00B5MMRT66.SGD"],"gpt_icon":0},{"id":"2527494402","title":"港股异动 | 石药集团(01093)涨超5% SYH2046片获中国临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2527494402","media":"智通财经网","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2527494402?lang=zh_cn&edition=full","pubTime":"2025-04-14 10:10","pubTimestamp":1744596600,"startTime":"0","endTime":"0","summary":"石药集团涨超5%，截至发稿，涨5.12%，报5.54港元，成交额2.45亿港元。消息面上，4月11日，石药集团宣布，集团开发的SYH2046片已获得国家药品监督管理局批准，可在中国开展临床试验。该产品是一款具有完全自主知识产权的全新结构first-in-class小分子药物，本次获批的临床试验适应症为急性心肌梗死后心力衰竭。临床前研究表明，该产品可显著改善疾病动物模型的心脏功能并降低心脏不良重构，且具有较高的安全性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-04-14/doc-inetaxma9008222.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00BZ08YS42.EUR","IE00BZ08YT58.USD","BK1583","LU1226287792.SGD","LU1152091168.USD","LU0880133367.SGD","01093","IE00B5MMRT66.SGD","LU1152091754.HKD","LU0501845795.SGD","BK1191","SG9999004220.SGD","LU1993786604.SGD","BK1515","LU1226288170.HKD","LU1226287875.USD","LU1807302812.USD","BK1576","BK1521","LU0140636845.USD","03347","LU1226288253.USD","LU1960683339.HKD","LU0326950275.SGD","IE0008369823.USD","LU0067412154.USD","LU1008478684.HKD","LU1226287529.USD","IE00BZ08YR35.GBP","IE0008368742.USD","LU0072913022.USD","BK1141","IE00B031HY20.USD","LU1951186391.HKD","IE00B543WZ88.USD"],"gpt_icon":0},{"id":"2518212605","title":"石药集团03月10日主力净流出4168万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2518212605","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518212605?lang=zh_cn&edition=full","pubTime":"2025-03-10 16:17","pubTimestamp":1741594654,"startTime":"0","endTime":"0","summary":"03月10日, 石药集团股价跌1.24%，报收4.79元，成交金额2.91亿元，换手率0.53%，振幅2.89%，量比0.78。石药集团今日主力资金净流出4168万元，上一交易日主力净流入3044万元。该股近5个交易日上涨3.02%，主力资金累计净流出246万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入2.46亿元，其中净流入天数为14日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310170954abf298bf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310170954abf298bf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BZ08YS42.EUR","IE00BZ08YT58.USD","LU1226287792.SGD","LU1152091168.USD","LU0880133367.SGD","01093","IE00B5MMRT66.SGD","LU1152091754.HKD","LU0501845795.SGD","BK1191","SG9999004220.SGD","LU1993786604.SGD","BK1515","LU1226288170.HKD","LU1226287875.USD","LU1807302812.USD","BK1521","LU0140636845.USD","LU1226288253.USD","LU1960683339.HKD","LU0326950275.SGD","IE0008369823.USD","LU0067412154.USD","LU1008478684.HKD","LU1226287529.USD","IE00BZ08YR35.GBP","IE0008368742.USD","LU0072913022.USD","IE00B031HY20.USD","LU1951186391.HKD","IE00B543WZ88.USD"],"gpt_icon":0},{"id":"2517445159","title":"石药集团：I类新药双功能融合蛋白药物JMT108获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2517445159","media":"财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517445159?lang=zh_cn&edition=full","pubTime":"2025-03-06 19:58","pubTimestamp":1741262311,"startTime":"0","endTime":"0","summary":"近日，石药集团发布JMT108获中国临床试验批准的公告。该产品是一种重组全人源抗PD-1且融合IL-15的双功能融合蛋白，通过靶向PD-1阳性肿瘤浸润免疫细胞，解除PD-1和PD-L1相互作用导致的免疫抑制，并通过PD-1抗体结合依赖性地激活IL-15下游信号通路，进一步促进相关免疫细胞的增殖和活化，从而达到增强的抗肿瘤疗效。本次获批的临床适应症为晚期恶性肿瘤。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306200013abeb4e69&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306200013abeb4e69&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0880133367.SGD","IE00B031HY20.USD","LU1226287529.USD","LU1951186391.HKD","BK1583","LU0140636845.USD","SG9999004220.SGD","LU1008478684.HKD","LU1226288170.HKD","03347","IE0008368742.USD","BK1141","LU0067412154.USD","LU0501845795.SGD","LU1152091754.HKD","LU0326950275.SGD","BK1191","LU1152091168.USD","LU1226287792.SGD","IE0008369823.USD","LU0072913022.USD","LU1960683339.HKD","LU1807302812.USD","BK1521","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","BK1576","IE00B543WZ88.USD","BK1515","IE00B5MMRT66.SGD","IE00BZ08YT58.USD","LU1226287875.USD","01093","LU1993786604.SGD","LU1226288253.USD"],"gpt_icon":0},{"id":"2517697100","title":"金十数据整理：每日港股市场要闻速递（3月6日 周四）","url":"https://stock-news.laohu8.com/highlight/detail?id=2517697100","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517697100?lang=zh_cn&edition=full","pubTime":"2025-03-06 09:06","pubTimestamp":1741223183,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["01093","00220","BK4543","01519","HK0000306701.USD","LU1226288253.USD","BK1539","IE00B5MMRT66.SGD","BIDU","BK0188","BK1515","IE00B19Z5X02.USD","HSCEI","01918","BK1594","LU0072913022.USD","07226","LU0287142896.SGD","LU0359202008.SGD","IE0008368742.USD","IE00B0169L03.USD","601288","LU1497733557.USD","02380","LU2039709279.SGD","HSTECH","00884","IE0034224299.USD","03900","LU1152091754.HKD","89888","LU0052750758.USD","IE00B0JY6N72.USD","LU0708995583.HKD","SG9999006597.SGD","09888","YANG","BK1549","00732","LU2328871848.SGD","00182","LU2778985437.USD","00305","BEST","01288","BK4502","LU0314109678.HKD","LU0501845795.SGD","03347","03143"],"gpt_icon":1},{"id":"2517916826","title":"石药预付款助力康宁杰瑞首次盈利，ADC管线成股价催涨剂丨看财报","url":"https://stock-news.laohu8.com/highlight/detail?id=2517916826","media":"钛媒体","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517916826?lang=zh_cn&edition=full","pubTime":"2025-03-05 20:24","pubTimestamp":1741177494,"startTime":"0","endTime":"0","summary":"3月5日，康宁杰瑞高开高走，收涨15.46%，最新总市值58.20亿港元。在这项合作中，康宁杰瑞有权收取高达6.16亿美元的一次性预付款及潜在里程碑付款，并可就各ADC产品向ArriVent收取分级销售特许权使用费。换句话说，石药集团的大额预付款不仅填平了公司日常经营产生的亏损窟窿，还将康宁杰瑞推向了盈利。值得注意的是，这并非石药集团首次与康宁杰瑞达成合作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/05202448546520.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["ADC","GLW","01093"],"gpt_icon":0},{"id":"2517299674","title":"石药集团(01093)开发的I类新药双功能融合蛋白药物JMT108获中国临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2517299674","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517299674?lang=zh_cn&edition=full","pubTime":"2025-03-05 17:22","pubTimestamp":1741166538,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团(01093)公布，该集团开发的I类新药双功能融合蛋白药物JMT108已获中华人民共和国国家药品监督管理局批准，可在中国开展临床试验。该产品是一种重组全人源抗PD-1且融合IL-15的双功能融合蛋白，通过靶向PD-1阳性肿瘤浸润免疫细胞，解除PD-1和PD-L1相互作用导致的免疫抑制，并通过PD-1抗体结合依赖性地激活IL-15下游信号通路，进一步促进相关免疫细胞的增殖和活化，从而达到增强的抗肿瘤疗效。本次获批的临床适应症为晚期恶性肿瘤。临床前研究显示，该产品的适应症广泛，在多种恶性肿瘤模型中具有显著的抗肿瘤作用及良好的安全性，具有较高的临床开发价值。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258054.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0067412154.USD","IE00BZ08YS42.EUR","LU0326950275.SGD","IE00BZ08YT58.USD","BK1141","BK1521","LU1226287529.USD","LU0880133367.SGD","IE00B5MMRT66.SGD","LU1951186391.HKD","LU1807302812.USD","BK1191","01093","IE0008369823.USD","BK1576","03347","LU1152091754.HKD","LU1152091168.USD","SG9999004220.SGD","LU1008478684.HKD","LU0501845795.SGD","LU0072913022.USD","IE00B031HY20.USD","LU0140636845.USD","IE00BZ08YR35.GBP","LU1226287792.SGD","LU1226288170.HKD","LU1226288253.USD","IE0008368742.USD","LU1226287875.USD","BK1583","IE00B543WZ88.USD","LU1993786604.SGD","BK1515","LU1960683339.HKD"],"gpt_icon":0},{"id":"2516128529","title":"金十数据整理：每日港股市场要闻速递（3月3日 周一）","url":"https://stock-news.laohu8.com/highlight/detail?id=2516128529","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516128529?lang=zh_cn&edition=full","pubTime":"2025-03-03 09:10","pubTimestamp":1740964249,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["09008","LU0348735423.USD","LU0417516738.SGD","BTC.USD.CC","03008","BK0196","BK1611","89888","LU0315179316.USD","YANG","00978","BK1104","01638","LU0229945570.USD","BTC.USD.HKCC","LU0326950275.SGD","01093","03042","BK1575","159875","03439","LU0072913022.USD","BIDU","IBIT","LU1993786604.SGD","HSCEI","09439","LU0762540952.USD","BK1609","000941.SH","09042","MSTU","LU1226287529.USD","00968","399941","BK0010","83042","HK0000320223.HKD","HSTECH","02600","601600","07226","03396","02097","09888","00434","ACH","160640","SG9999004220.SGD","00017"],"gpt_icon":1},{"id":"2516560442","title":"石药集团只能往外跑了","url":"https://stock-news.laohu8.com/highlight/detail?id=2516560442","media":"财讯先锋","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516560442?lang=zh_cn&edition=full","pubTime":"2025-03-02 08:30","pubTimestamp":1740875431,"startTime":"0","endTime":"0","summary":"整体看来石药集团表现不及预期，同时集团在国际授权业务方面的新动向也备受关注。01不难发现，药品集采政策对石药集团的业绩产生了显著冲击。在二级市场上，石药集团股价表现相对低迷。石药集团今年频繁的对外授权动作，展现了这家老牌制药企业由仿转创的决心，虽然已经取得了一定进展，但面对仿制药业务下滑与创新药成长的过渡期挑战，石药集团仍需在经验积累中实现质的突破才行。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250302084528abe3ccad&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250302084528abe3ccad&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BZ08YS42.EUR","IE00BZ08YT58.USD","LU1226287792.SGD","LU1152091168.USD","LU0880133367.SGD","01093","IE00B5MMRT66.SGD","LU1152091754.HKD","LU0501845795.SGD","BK1191","SG9999004220.SGD","LU1993786604.SGD","BK1515","LU1226288170.HKD","LU1226287875.USD","LU1807302812.USD","BK1521","LU0140636845.USD","LU1226288253.USD","LU1960683339.HKD","LU0326950275.SGD","IE0008369823.USD","LU0067412154.USD","LU1008478684.HKD","LU1226287529.USD","IE00BZ08YR35.GBP","IE0008368742.USD","LU0072913022.USD","IE00B031HY20.USD","LU1951186391.HKD","IE00B543WZ88.USD"],"gpt_icon":0},{"id":"2514349360","title":"石药集团：注射用西罗莫司(白蛋白结合型)于中国获突破性治疗认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2514349360","media":"格隆汇资讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514349360?lang=zh_cn&edition=full","pubTime":"2025-02-28 18:00","pubTimestamp":1740736834,"startTime":"0","endTime":"0","summary":"格隆汇2月28日丨石药集团公告，集团开发的注射用西罗莫司获中华人民共和国国家药品监督管理局授予突破性治疗认定，拟定适应症为单药用于恶性血管周围上皮样细胞瘤。此前已有口服制剂的西罗莫司获批上市，主要适用于预防接受肾移植患者的器官排斥。同时，该产品拓展了西罗莫司的应用领域，有望实现治疗mTOR信号通路驱动的一系列疾病。恶性PEComa国内尚无标准治疗，存在未被满足的临床需求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228180046989630f0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228180046989630f0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BZ08YT58.USD","LU1993786604.SGD","LU0140636845.USD","LU1960683339.HKD","IE00BZ08YS42.EUR","LU1226287792.SGD","LU1008478684.HKD","01093","LU1226287529.USD","IE0008369823.USD","LU0067412154.USD","LU0072913022.USD","LU1152091168.USD","LU0326950275.SGD","BK1521","LU1951186391.HKD","BK1191","IE00B031HY20.USD","SG9999004220.SGD","LU1152091754.HKD","LU1807302812.USD","IE00BZ08YR35.GBP","LU1226287875.USD","IE00B543WZ88.USD","LU0501845795.SGD","LU0880133367.SGD","LU1226288170.HKD","LU1226288253.USD","IE0008368742.USD","IE00B5MMRT66.SGD","BK1515"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cspc.com.hk","stockEarnings":[{"period":"1week","weight":0.0904},{"period":"1month","weight":0.1266},{"period":"3month","weight":0.2341},{"period":"6month","weight":-0.1512},{"period":"1year","weight":-0.0401},{"period":"ytd","weight":0.136}],"compareEarnings":[{"period":"1week","weight":0.0391},{"period":"1month","weight":-0.1279},{"period":"3month","weight":0.0786},{"period":"6month","weight":0.0122},{"period":"1year","weight":0.2959},{"period":"ytd","weight":0.0497}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"石药集团有限公司是一家主要从事生产及销售药品的投资控股公司。该公司通过三个分部运营其业务。成药分部从事研发、生产及销售药品以及授权业务。原料产品分部从事生产及销售粉状维生素C及抗生素产品。功能食品及其他分部从事制造及销售功能食品产品（包括咖啡因食物添加剂、无水葡萄糖、阿卡波糖及维生素C含片）、提供医疗服务及其他。该公司的产品治疗领域包括神经系统、抗肿瘤、抗感染、心血管、呼吸系统、消化代谢等其他领域。该公司在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.516129,"avgChangeRate":0.005416},{"month":2,"riseRate":0.741935,"avgChangeRate":0.096729},{"month":3,"riseRate":0.483871,"avgChangeRate":0.020701},{"month":4,"riseRate":0.612903,"avgChangeRate":0.057766},{"month":5,"riseRate":0.6,"avgChangeRate":0.038129},{"month":6,"riseRate":0.333333,"avgChangeRate":0.004615},{"month":7,"riseRate":0.354839,"avgChangeRate":0.000119},{"month":8,"riseRate":0.419355,"avgChangeRate":0.009776},{"month":9,"riseRate":0.516129,"avgChangeRate":0.002662},{"month":10,"riseRate":0.580645,"avgChangeRate":0.016021},{"month":11,"riseRate":0.451613,"avgChangeRate":0.005451},{"month":12,"riseRate":0.483871,"avgChangeRate":-0.01556}],"exchange":"SEHK","name":"石药集团","nameEN":"CSPC PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.1","shortVersion":"4.33.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"石药集团(01093)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供石药集团(01093)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"石药集团,01093,石药集团股票,石药集团股票老虎,石药集团股票老虎国际,石药集团行情,石药集团股票行情,石药集团股价,石药集团股市,石药集团股票价格,石药集团股票交易,石药集团股票购买,石药集团股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"石药集团(01093)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供石药集团(01093)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}